| Follow Us:

Life Sciences : Innovation + Job News

46 Life Sciences Articles | Page: | Show All

Sickweather Combines Illness Mapping With Social Networking

If you're trying to beat the sniffles and sneezes of cold season, Sickweather is looking for you.
The new illness mapping social networking site offers users the opportunity to see maps of
local illness “hot spots” based on data collected from users, Facebook status updates and
Twitter streams.

“With Sickweather, we hope to offer a new and useful resource to help people stay healthy. It
really is baffling to me that people check the weather report every day before they leave the
house or before they go on a trip, but health related symptoms go ignored. If people prepare
for the weather by bringing their umbrella with them, why don't they do a similar thing by
drinking an extra glass of orange juice in the morning to boost their immune system?” asks
Sickweather COO James Sajor.

The Baltimore based start-up behind Sickweather is preparing to launch the social networking
site , which is currently in its final Beta testing phase. The brainchild of entrepreneur
Graham Dodge, formerly involved with Crime Map, and marketing expert James Sajor,
Sickweather aims to not only help healthy people avoid virulent spots, but also allow people
with compromised immune systems and their families a resource to help them avoid exposure
to a potentially life threatening germ.

“I had recently moved back to Baltimore to take care of my mother, who was diagnosed
with an advanced stage of cancer. She was going through a variety of treatments, and her
immune system was severely compromised. That meant that I could not get sick. It would
actually have been a life-and-death situation if I caught a common cold. I was extra careful
when I left the house. So when Graham approached me, I immediately saw the value in the
idea,” says Sajor.

In addition to the final beta testing of the site, Sickweather is also developing a mobile app
version for Android and iPhone.

Writer: Amy McNeal
Source: James Sajor, Sickweather

http://sickweather.com/

Maryland Tops in Life Sciences Research

Maryland leads the country in university conducted life sciences research per capita, according to a new report published by The Maryland Department of Business and Economic Development. The Life Sciences Maryland: Jobs and Economic Impact Report was released by Governor O'Malley at the BIO 2011 International Conference in Washington, DC.

The life sciences sector has been a major source of new job growth in Maryland in the last decade. Between 2002 and 2010, the life sciences sector was responsible for one third of Maryland's job gains. Life sciences jobs pay an average of 76% more than other jobs in the state, with an average salary of more than $91,000. The majority of the region's jobs in life sciences are in Research, Testing and Medical Labs, and Drugs and Pharmaceuticals. These specializations account for 94% of Maryland's life sciences jobs.  

Life sciences activity, including private sector jobs, Federally related jobs, and academic activity accounts for 71,618 Maryland jobs, or 3% of all jobs in the state. There are 15 Federal facilities, 16 universities or colleges, and over 500 private companies conducting life sciences research in Maryland. With more than 1700 private companies supporting and producing products for the life sciences sector in the state, Maryland ranks fifth in the country for overall concentration of jobs that are directly tied to life sciences.


Writer: Amy McNeal
Source: Maryland Department of Business and Economic Development

International Dyslexia Association Launches Parent Initiative

The International Dyslexia Association has launched an initiative to help parents of dyslexic and learning disabled children connect with one another and get the information that they're looking for to help their children. The initiative includes a lower membership price for parent members, a new bi-monthly news letter, and other tools for parent members.

The centerpiece of the new program is a website that allows parents of dyslexic and learning disabled children to connect with other parents dealing with the same issues. The private, secure forum allows parent members to post questions, have conversations, post photos and videos, and make connections within the dyslexia and learning disability community. The connection site is currently being tested in 12 markets.

The Timonium based International Dyslexia Association has up to this point been a resource that was tailored to the needs of clinicians, researchers, educators and other professionals in fields that contribute to dyslexia research and education. The initiative to make the IDA accessible to parents was spurred by large numbers of parent calls and emails to the IDA.

"We get phone calls and emails from parents all over the country. Our goal is to support our parents in any way that we can. One of the things that we see the most is that parents want to connect with other parents," says Kristi Bowman, Director of Development for the International Dyslexia Association.

The IDA will be continuing the parent outreach program with new informational materials designed for parents. The new parent focused informational brochures and other learning materials will be available later this year.


Writer: Amy McNeal
Source: Kristi Bowman, International Dyslexia Association


Integrated BioTherapeutics Continues to Grow

Integrated BioTherapeutics, a firm that specializes in developing vaccines for infectious diseases and countermeasures for bio-terrorism threats, is growing. The company recently moved into a new, larger facility in the Gaithersburg Accelerator.

The move to a larger facility was spurred by the need for more secure, dedicated lab space as the company develops new vaccine technology. Integrated BioTherapeutics was recently awarded a grant from The National Institute of Allergy and Infectious diseases to develop a second-generation Ebola vaccine in partnership with the University of Texas Medical Branch. The company also received a grant from NIAID in 2010 for research and development of a Staphylococcus vaccine. The second phase of that research project is due to wrap up this year. Integrated BioTherapeutics is currently working on projects to create vaccines for a host of infectious diseases, including Dengue Fever, Staphylococcus, Streptococcus, Marburg Viruses and Ebola. 

"We have a drive to make something that changes the world, to create a vaccine that mutes something that effects people. We strive to help others do that too," says Rob Galioto, Director of Business Development at Integrated BioTherapeutics.

Integrated Bio Therapeutics was recently honored at the inaugural TEDCO ICE awards as Company of the Year. The award was given in recognition of the company's growth. Since its launch in 2008, Integrated BioTherapeutics has secured over $30 million in government research funding, and increased its staff size from one employee to 30. The company is expecting to add five to ten staff positions in the next year.

Author: Amy McNeal

Source: Rob Galioto, Integrated BioTherapeutics


Teva, UMB Team Highlight Advances in MS Treatment

Dr. Kenneth P. Johnson, longtime head of neurology at the University of Maryland-Baltimore, joined representatives of international pharmaceutical giant Teva at the UMB BioPark on February 24 to talk about advances in the treatment of the autoimmune disease multiple sclerosis (MS) that took place as a result of research at Israel's Weizmann Institute of Science and UMB.

Dr. Johnson spearheaded efforts to ease self-injection of Copaxone by MS patients, and pointed out Baltimore's unique status in life sciences and more specifically in medicine: "There are a few primary places on the map, one being Baltimore, where you can expect new development and superior patient care." Across Maryland, the region's advantage is even heavier: "Between Johns Hopkins, UMB, and the National Institutes of Health [in Bethesda], very few places in the country even come close to what is available here."

The Maryland/Israel Development Center, which promotes bilateral trade and encourages Israeli companies to establish their North American bases in Maryland, sponsored the event. John Hassler, VP of Marketing at Teva Neuroscience, also spoke about Teva's dual role as both the largest manufacturer of generic drugs in the world -- one in every six U.S. prescriptions is filled with a Teva product -- and maker of branded treatments like Copaxone. Teva worked with Dr. Johnson to make Copaxone easy to use, and the company achieved positive results over the years for consistent treatment by introducing nurses as trainers and assuring proper administration through consultation with physicians.

"One of the key issues with MS is that we don't know what causes it, so there are multiple methods of treating it," Hassler said.

Over 2.5 million people are affected by MS worldwide.

Writer: Sam Hopkins
Sources: Dr. Kenneth Johnson, UMB, John Hassler, Teva Neuroscience

University of Maryland Baltimore to Use $45M Gift to Create New Research Center

The University of Maryland Medical School has received a $45 million private gift from the family of a grateful patient.

UMMS will use the multi-million dollar gift to establish the nation's only research enterprise devoted to the study of autoimmune and inflammatory diseases such as celiac disease, multiple sclerosis, chronic obstructive pulmonary disease, asthma, and Type-1 diabetes.

The gift, from Indiana couple Ken and Shelia Cafferty, is the largest private donation in the history of the University System of Maryland. The planned research enterprise will be a full-fledged, multidisciplinary academic organization that includes and expands upon two of the school's outstanding research centers, the Mucosal Biology Research Center and the Center for Celiac Research. Alessio Fasano, M.D., a world renowned celiac disease researcher and professor of pediatrics, medicine and physiology at the School of Medicine, will direct the new research enterprise. Dr. Fasano is director of the Mucosal Biology Research Center and the Center for Celiac Research.

"For years, my wife struggled with severe symptoms, with no diagnosis and no treatment for her condition," says Ken Cafferty, a businessman from Carmel, Indiana, who is making the gift with his wife, Shelia, a registered nurse. "I endured this struggle with her, until Dr. Fasano and his staff at the Center for Celiac Research finally found answers for us, diagnosing Shelia with gluten sensitivity. We are making this gift hoping that this new enterprise will help provide answers for other families in the same position, and hopefully make strides toward a cure to provide permanent relief for patients like Shelia."

As is the case with all new research enterprises (institutes or centers), establishment of the research enterprise for autoimmunity research is subject to approval from University of Maryland School of Medicine leadership; a vote will take place in November.

The planned enterprise will have three divisions: one focused on celiac disease, the second on mucosal biology, and a third focused on microbe/host interaction. The third division, the newest of the three, will examine the intersection between the human body and the microbes that inhabit it. Faculty will work closely with faculty at the University of Maryland Institute for Genome Sciences, located in the University of Maryland BioPark in West Baltimore.

"We are assembling a critical mass of multidisciplinary expertise, building the best infrastructure that we can in order to investigate inflammation and autoimmunity from every possible medical and scientific perspective," says Dr. Fasano.

The institute's scientists will use celiac disease as a model for research into autoimmune disorders such as multiple sclerosis and diabetes. Autoimmune disorders occur when the body is triggered to misdirect its immune response and attack itself. Celiac disease is of particular value for the investigation of autoimmunity and inflammatory disease because it is the only autoimmune disorder for which scientists have identified a trigger � in this case, gluten, a protein found in wheat that is nearly ubiquitous in the contemporary human diet.

Source: University of Maryland Medical Center
Writer: Walaika Haskins

Profectus BioSciences gets $6.25M in grants and contracts from NIAID

Profectus BioSciences, Inc., a technology-based vaccine company devoted to the treatment and prevention of chronic viral diseases, has received $6.25 million in grants and contracts from the National Institute of Allergy and Infectious Disease (NIAID), including three Small Business Innovative Research (SBIR) grants from the Division of AIDS, National Institutes of Health totaling $2.9M. These grants are focused on optimizing the Company's portfolio of genetic adjuvants.

Profectus BioSciences seeks to harness the immune system to treat and prevent viral diseases and cancers through the delivery of proprietary prime/boost vaccines.

"Along with IL-12, our portfolio of genetic adjuvants provides us with a toolbox of options to optimize our heterologous prime/boost vaccines. These awards provide significant validation to our scientific approach and accelerate our efforts to develop therapeutic vaccines against HCV, HPV, HSV, and HIV that will have significant clinical impact," says John Eldridge, chief science officer at Profectus BioSciences.

Profectus BioSciences also received $2.75M in continued contract support from the Division of AIDS to develop its recombinant Vesicular Stomatitis Virus (rVSV) platform as an HIV vaccine. VSV is a negative-strand, non-segmented RNA virus from the order Mononegavirales that has been redesigned to enable delivery of vaccine immunogens. VSV is a particularly attractive candidate for this purpose because its genome can potentially host more than one foreign gene and it contains its own Profectus BioSciences is utilizing this technology along with its pDNA platforms to develop effective therapeutic vaccines against HCV, HPV, HSV, as well as HIV.

This funding is in addition to the $4.4M in grants announced earlier this week to support the Company's HIV prophylactic vaccine program.

Source: Profectus BioSciences
Writer: Walaika Haskins


University of MD partnership with UMBC, UMB nabs $7.9M from NIH for superconducting research magnet

The University of Maryland, in partnership with the University of Maryland, Baltimore (UMB) and University of Maryland Baltimore County (UMBC), has received a $7.9 million federal grant to acquire a superconducting 950 MHz Nuclear Magnetic Resonance (NMR) magnet that will help researchers unravel the mysteries of molecules and develop new agents to treat cancer, AIDS and other diseases.

The grant is among the largest of its kind ever awarded by the National Center for Research Resources (NCRR), part of the National Institutes of Health. The funds were made available through the American Recovery and Reinvestment Act of 2009.

The NMR is scheduled to be installed in November, 2011 at the University of Maryland School of Medicine in Baltimore. It will be shared equally among the three campuses and used by researchers throughout the Mid-Atlantic region. Only one other site in the United States currently has a 950 MHz NMR spectrometer, and the University of Maryland partnership will be the only academic institutions in the country to have this powerful technology.

David Fushman, professor of chemistry and biochemistry at the University of Maryland, is a co-director of the grant, and will lead the College Park team that includes several biochemists and cell biologists whose research will be enhanced by the new NMR spectrometer.

David J. Weber, professor of biochemistry and molecular biology at the University of Maryland School of Medicine and director of the NMR core facility there, and AIDS researcher Michael F. Summers, professor of chemistry and biochemistry at UMBC, are co-directors with Professor Fushman.

The eight-ton magnet produces a supercharged magnetic field that enables scientists to investigate the three-dimensional structure of biological molecules and study their interaction with the highest degree of resolution.

"This 950 Mhz NMR is optimal for studying large molecules," explains Fushman, an expert in protein structure and dynamics who is associated with the university's Center for Biomolecular Structure and Organization (CBSO). "This will allow us to move into studying larger protein complexes that include more than 1000 amino acids. We can begin to decipher interactions between proteins that we could not easily do before."

The 950 MHz NMR spectrometer will enable University of Maryland researchers to delve deeper into the molecular mechanisms of proteins and nucleic acids in the body and to provide the much needed fundamental information from which drug therapies and other medical treatments can be based. Researchers at the University of Maryland School of Medicine will utilize the technology in many areas of cancer research, including drug development, while UMBC researchers will focus on AIDS research.

Source: University of Maryland, Baltimore
Writer: Walaika Haskins


University of Maryland Medical School nabs $12.3M from NIH to renovate its labs

TheUniversity of Maryland School of Medicine has received $12.3 million in National Institutes of Health (NIH) grants to renovate research laboratories of the University of Maryland Marlene and Stewart Greenebaum Cancer Center and to build core facilities � centralized areas of technology and expertise � that will provide key support services to cancer researchers. The funds are part of $1 billion in funding made available by the federal government through the American Recovery and Reinvestment Act for construction or renovation of research facilities.

The NIH's National Center for Research Resources (NCRR) has awarded a $5 million C06 construction grant to renovate laboratories on the eighth floor of the School of Medicine's Bressler Research Building at 655 W. Baltimore St. Another $7.3 million G20 Core Renovation, Repair and Improvement grant will be used to consolidate existing core laboratories and build new facilities on the sixth and seventh floors of the Bressler Building.

These new core laboratories will provide "shared services" to cancer researchers and other scientists at the University of Maryland School of Medicine and other professional schools at the University of Maryland, Baltimore. Many of these support services benefit the cancer center, which is part of the School of Medicine and the University of Maryland Medical Center.

"These NCRR grants will enable us to build new, modern laboratory facilities for our researchers that hopefully will pave the way for major breakthroughs in cancer research. We are continually expanding our research program, and constructing state-of-the-art laboratories is critical to that effort," says Kevin J. Cullen, M.D., director of the University of Maryland Marlene and Stewart Greenebaum Cancer Center and professor of medicine and director of the Program in Oncology at the University of Maryland School of Medicine.

"Our cancer center has been recognized by the National Cancer Institute for its scientific excellence, and our faculty members conduct some of the most innovative and promising cancer research in the nation. These new laboratories will not only facilitate this work but also will help us to recruit more top-tier scientists to our cancer center," says E. Albert Reece, M.D., Ph.D., M.B.A., acting president of the University of Maryland, Baltimore, and dean of the University of Maryland School of Medicine.

The newly renovated space will be used by individual molecular and structural biology researchers and will also house core labs for confocal microscopy, proteomics, flow cytometry, tissue-culturing and tissue-related services such as histology and immunohistochemistry, as well as the Genomics Core Facility, which provides cutting-edge genomic support for researchers.

The renovation on the eighth floor of the Bressler Building is scheduled to begin in November and will be completed in August 2011. The construction on the sixth and seven floors will begin upon completion of the eighth floor renovations and be finished by August 2012.


Source: University of Maryland Medical School
Writer: Walaika Haskins


College Park researchers study use of poplar trees for new biofuel with $3.2M grant

First it was corn. Then came sugar cane, cooking oil, switch grass, and you name it researchers have tried it in the name of saving the planet from carbon emissions.

But, just when we all thought scientists had exhausted the possibilities, an interdisciplinary team of researchers from the University of Maryland College Park and Bowie State University have begun working on ways to turn poplar trees into high-yield crops for biofuels including ethanol, the renewable biofuel used in gasoline blends and flex-fuel vehicles. 

Funded by a $3.2 million, four-year grant from the National Science Foundation's Plant Genome Research Project, which supports research on plants seen as having economic and agricultural importance, researchers Gary Coleman, Ganesh Sriram and Jianhua Zhu of College Park and George Ude of Bowie State are using the recently completed poplar genome to look for ways to improve the tree's nitrogen processing capability, which would enhance its growth rate and feasibility for use in fuel production.

Although corn has long been the crop of choice for biofuel production in the U.S.,  though it is renewable, home-grown (unlike foreign oil) and plentiful, it may not be the best solution.

"We need to develop an alternative crop that we use exclusively for biofuels and not food," says Sriram, assistant professor of chemical and biomolecular engineering at the University of Maryland's A. James Clark School of Engineering.

Enter poplar trees (also known as cottonwood or aspen), which is already commonly cultivated for the production of paper and timber.

"What we want are trees like poplar that grow fast and efficiently so they can become the raw material for cellulosic [fiber-based] biofuel," Sriram says. "The carbon found in poplar could be converted into fuels just like the sugars we extract from corn."

Coleman, lead researcher and an associate professor of plant science and landscape architecture in the university's College of Agriculture and Natural Resources says there are many advantages of a poplar crop over traditional biofuel sources.

"Growing trees doesn't eat into farmland, and trees don't require a lot of maintenance during their growth cycle," he explains. "A dedicated energy crop like poplar would contribute to the development of a sustainable and renewable energy system."

While the hybrid trees would be grown on plantations and harvested without affecting existing woodlands, simply growing acres of poplar trees to convert into biofuel isn't enough to solve current fuel problems. Researchers already know how to make ethanol from fibrous plants, but for poplar to be truly effective as a biofuel source, its growth cycle needs to speed up and become more efficient. One of the keys to doing so is to understand how it stores and cycles nitrogen, since nitrogen is an important factor in the growth and productivity of trees and crops.

The fertilizers that help produce big harvests are rich in nitrogen, but are expensive and must be reapplied each year. Poplar is a perennial plant, capable of pulling nitrogen from its leaves, storing it through the winter, and redistributing it in the spring. And while a crop like corn must be replanted each year, a poplar tree is capable of regrowing itself from its roots after being cut, and may go through several cycles of growth and harvest throughout its life before a new tree needs to replace it.

"Both the growth in the spring and regrowth from roots after the stems are harvested depend on the availability of stored nitrogen," Coleman says. "The data we collect will allow us to understand mechanisms of nitrogen cycling, determine how to increase the rates of the cellular reactions, and identify the genes that play a crucial role in the process. Eventually, we should be able to breed a variety of poplar with a more efficient nitrogen process, optimized for growth and rapid maturity."

Source: University of Maryland College Park
Writer: Walaika Haskins


Need a job? Institute for Genome Sciences is hiring for multiple positions

With some $60 million in federal grant money a year, the Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine, a new international research center in Baltimore's BioPark, has multiple positions available for qualified personnel.

IGS scientists research the genomics of infectious diseases, human microbial metagenomics, and human genomics. Because of expanding research and the growth of genomics, IGS has multiple open positions, particularly in the bioinformatics group, the application of information technology to biological data, using computational and statistic techniques. This enables IGS to sequence samples from which people in the bioinformatics department annotate and analyze the complex genomic data.

The company is looking for motivated and talented individuals to join its informatics and scientific tream. IGS' expanding growth has led to multiple openings for software engineers, analysts, postdoc fellows and researchers.

Successful candidates will benefit from a community of interactive research labs, bioinformatics programmers and analysts along with a variety of sequencing, and computational resources available at this world-class institute.

New public health lab gets the go ahead

The Board of Public Works has approved an agreement between the Department of Health and Mental Hygiene (DHMH), the Department of General Services and the Maryland Economic Development Corporation (MEDCO) to begin planning a new state-of-the-art public health laboratory to replace the antiquated and crowded facilities at the State Office Complex on West Preston Street. The new facility -- to be built by September 2013 -- will be located at the East Baltimore redevelopment project known as the Science and Technology Park at Johns Hopkins.

The Board -- comprised of the Governor, State Comptroller Peter Franchot, and State Treasurer Nancy K. Kopp -- approved the $6.45 million expenditure to begin the design phase of the new laboratory, which will help the state respond more rapidly to such public health events as newly emerging epidemics, foodborne outbreaks and incidents of bioterrorism. The laboratory is expected to have a price tag of $180 million, which will be funded by Lease Revenue Bonds issued by MEDCO and backed by the DHMH lease.

"The new public health lab will advance our goal of providing Maryland families the best public health service and protection that modern science and technology can offer," says Gov. O'Malley. "This state-of-the-art facility maximizes our abilities to protect the health and well-being of all Marylanders under a creative financing agreement that minimizes the cost to taxpayers."

As a member of the national Laboratory Response Network, the State laboratory acts as an early warning system for public health threats and shares this information with other state and federal agencies so that threats such as the drug resistance to H1N1 influenza can be identified, tracked, and quickly contained.

"As the H1N1 (Swine) flu experience clearly demonstrated, the public health laboratory is the backbone of Maryland's public health system," says John M. Colmers, DHMH Secretary. "The investment we are making today will provide Maryland families with decades of protection against disease and illness."

The structure will be a significantly more efficient building than the old facility that opened in 1974. The new laboratory will provide a 29 percent increase in useable space over the current facility, growing from 100,000 net assignable square feet to 129,000 net assignable square feet, while decreasing the actual gross square footage from the current 227,000 to an estimated 200,000 gross square feet. It will have 41 high-level biosafety laboratories, an infrastructure to support sophisticated instruments and equipment, and more sophisticated levels of security.

The new facility will be financed through the Maryland Economic Development Corporation (MEDCO), an instrumentality of the State created by the General Assembly to assist private and government agencies in expanding and modernizing existing enterprises in Maryland. Forest City-New East Baltimore Partnership, a nationally recognized developer of laboratory facilities and chosen by East Baltimore Development, Inc. as the developer for the Science and Technology Park at Johns Hopkins, will be the developer for the new public health laboratory.

Source: Board of Public Works
Writer: Walaika Haskins


New DNA test uses nanotechnology to hunt down early signs of cancer

Johns Hopkins University (JHU) researchers have developed a highly sensitive test that searches for DNA attachments that often serve as early warning signs of cancer. The new technology uses tiny crystals called quantum dots to detect the presence and quantity of certain DNA changes. It could be used to detect people at risk for developing cancer and let doctors know the effectiveness of a particular cancer treatment.

Published in the August issue of the journal Genome Research, the test was developed by Jeff Tza-Huei Wang, an associate professor of mechanical engineering and colleagues at the Johns Hopkins Kimmel Center.

"If it leads to early detection of cancer, this test could have huge clinical implications," said Jeff Tza-Huei Wang, an associate professor of mechanical engineering whose lab team played a leading role in developing the technique. "Doctors usually have the greatest success in fighting cancer if they can treat it in its early stage."

Writer: Walaika Haskins

Source: JHU

UMBI technology spawns Plasmonix spinoff

The University of Maryland Biotechnology Institute (UMBI) has reached a deal with Plasmonix, Inc. that grants the company license to its metal-enhanced fluorescence (MEF)patents. The agreement stipulates that Plasmonix creates a new spin-off company located in Maryland.

MEF technology dramatically increases the sensitivity and speed of a broad range of diagnostic and biological assays for DNA and for proteins. It has multiple applications in clinical diagnostics and homeland security.

One real world application of MEF technology will detect the elevated enzymes associated with a heart attack in 20 seconds as a patient is transported via ambulance to the hospital. From a security perspective, it can be used to rapidly detect minute amounts of biohazard agents.

The new company will be dedicated to bringing the MEF technology developed by UMBI's Institute of Flourescence to the marketplace.

"MEF is a major breakthrough for biological diagnostics and the spin-off of Plasmonix is just one example of the ways that UMBI addresses important human needs by bringing new technologies from the laboratory bench to the marketplace," says Dr. Jonathan Gottlieb, director of Technology Transfer and Commercialization for UMBI.

$600K NSF grant to turn scientists into entrepreneurs

Johns Hopkins University (JHU) and the University of Maryland, Baltimore County (UMBC) have teamed up to train postdoctoral research fellows from the National Institute of Health (NIH) and other federal labs in the region on starting technology-based companies.

The joint project, a result of a $600,000 grant from the National Science Foundation (NSF) through its Partnerships for Innovation program, will establish an ACTiVATE at NIH program in Montgomery County. It builds on a successful ACTiVATE program at UMBC that trains mid-career women to start companies using technologies developed at area universities and research institutions.

"We are pleased to expand the ACTiVATE® model to Montgomery County and to offer the program to the talented group of scientists working as postdocs at NIH and other federal labs in the region. In the course of four years, the program at UMBC has trained 92 women and launched over 25 companies; we hope to bring that same success to this new venture," says Stephen Auvil, assistant vice president for research at UMBC and a co-principal investigator on the NSF award

Intended to stem the flow of highly skilled, postdoctoral fellows at NIH who leave the state each year, the new program will provide postdocs with the training and support needed to start new companies in Maryland or pursue an entrepreneurial career.

Offering postdocs the opportunity to develop new skills that transform research into viable businesses will lead to rewarding career paths and contribute to the growth of Maryland's life sciences industry, and also advance medical science by moving emerging technologies from the lab to the marketplace.

The program will recruit postdoc fellows and members of the business community to form interdisciplinary teams and pursue opportunities for startup companies. The JHU Carey Business School will receive funding under the award to offer ACTiVATE at NIH at their Shady Grove campus in Rockville.


Writer: Walaika Haskins
Source: Stephen Auvil, UMBC
46 Life Sciences Articles | Page: | Show All
Share this page
0
Email
Print
Signup for Email Alerts